About Fibronectin type III domain-containing protein 8
Fibronectin type III domain-containing protein 8 (FNDC8) is a protein
from Homo sapiens identified by UniProt accession
Q8TC99, 324 residues long.
MolForge cross-references it against 0 known binders and
11 disease associations.
Target properties
| Protein name | Fibronectin type III domain-containing protein 8 |
|---|
| UniProt accession | Q8TC99 |
|---|
| Gene | FNDC8 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 324 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (11)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.20
- Hereditary breast and ovarian cancer syndrome · score 0.12
- sphingomyelin measurement · score 0.02
- cancer · score 0.01
- juvenile dermatomyositis · score 0.01
- Familial gastric cancer · score 0.00
- colon adenocarcinoma · score 0.00
- neoplasm · score 0.00
- squamous cell lung carcinoma · score 0.00
- central nervous system cancer · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8TC99-F1 | alphafold | PREDICTED | 59.98 | — |
Amino-acid sequence (324 residues)
MASEALHQVG DGEEAVLKKE NFNMMNALDQ LPKPFSNPKS MNRTVTTKGL PLASKGNLVN FLEDDTINLL KPLPVEDSDC SSDETSISAF SSTLLNPIKL AVTQPNSSFF AGMLEGELNK LSFSPMAKNA ENEDLALGPC PCPSKSQMAT RGLLDLDNPE LETETSSTHS ESSVVVDLPD TPFIFEHTVN NSTAVISWTY ALGKQPVSFY QLLLQEVAKT QENELPEAKN RPWIFNKILG TTVKLMELKP NTCYCLSVRA ANTAGVGKWC KPYKFATLAT DFSSFPENYP IQITVRRKEP RQKIVSIGPE EMRRLEDLEY LFPC
Explore Fibronectin type III domain-containing protein 8 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets